NCT06376799 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A
The effects of advance care planning on end-of-life care: a systematic review. Palliat Med. 2014 Sep;28(8):1000-25. doi: 10.1177/0269216314526272. Epub 2014 Mar 20.
Kubi B, Istl AC, Lee KT, Conca-Cheng A, Johnston FM
Advance Care Planning in Cancer: Patient Preferences for Personnel and Timing. JCO Oncol Pract. 2020 Sep;16(9):e875-e883. doi: 10.1200/JOP.19.00367. Epub 2020 Apr 13.
Peck V, Valiani S, Tanuseputro P, Mulpuru S, Kyeremanteng K, Fitzgibbon E, Forster A, Kobewka D
Advance care planning after hospital discharge: qualitative analysis of facilitators and barriers from patient interviews. BMC Palliat Care. 2018 Dec 5;17(1):127. doi: 10.1186/s12904-018-0379-0.
Rietjens JAC, Sudore RL, Connolly M, van Delden JJ, Drickamer MA, Droger M, van der Heide A, Heyland DK, Houttekier D, Janssen DJA, Orsi L, Payne S, Seymour J, Jox RJ, Korfage IJ; European Association for Palliative Care
Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol. 2017 Sep;18(9):e543-e551. doi: 10.1016/S1470-2045(17)30582-X.

Which Health-care Professional(s) to Talk About Advance Care Planning ? The Point of View of French Patients Followed in the Context of an Oncological Disease.

Details for clinical trial NCT06376799

Clinical trial NCT06376799 - References